Andrew Butcher describes why securing stakeholder buy-in to high-cost new therapies is critical to managing the pharmaceutical industry’s reputation in the November/December 2015 issue of PharmaVOICE. To read more, click here.
Evaluating Medicare Stars for cardiovascular disease patients
Considering that cardiovascular disease (CVD) remains the leading cause of death in the United States, particularly affecting the growing population of...